Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy

This study has been completed.
Information provided by:
Amgen Identifier:
First received: May 16, 2005
Last updated: January 14, 2010
Last verified: January 2010
The purpose of this study is to compare the effect of darbepoetin alfa against placebo for the treatment of anemia in subjects with non-myeloid malignancies receiving multicycle chemotherapy.

Condition Intervention Phase
Non-Myeloid Malignancies
Drug: Darbepoetin alfa
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy

Resource links provided by NLM:

Further study details as provided by Amgen:

Primary Outcome Measures:
  • Incidence of red blood cell (RBC) transfusion from week 5 to End of Treatment Period (EOTP) [ Time Frame: from week 5 to EOTP ]

Secondary Outcome Measures:
  • Incidence of achieving a hemoglobin concentration of greater than or equal to 11 g/dL in the absence of RBC transfusions in the preceding 28 days from week 5 to EOTP [ Time Frame: from week 5 to EOTP ]
  • Number of RBC transfusions from week 5 to EOTP [ Time Frame: from week 5 to EOTP ]
  • Change in FACT-Fatigue subscale score from baseline to EOTP [ Time Frame: from baseline to EOTP ]
  • Change in FACT-G Physical Well-being subscale from baseline to EOTP [ Time Frame: from baseline to EOTP ]
  • Incidence and severity of adverse events [ Time Frame: throughout study ]
  • Incidence of hemoglobin concentration greater than 13.0 g/dL at any time on study [ Time Frame: at any time on study ]
  • Change in FACT-G total score from baseline to EOTP [ Time Frame: from baseline to EOTP ]
  • Incidence of an increase in hemoglobin concentration greater than or equal to 2 g/dL in a 28-day window and any negative clinical consequences [ Time Frame: throughout study ]
  • Change in EQ-5D Thermometer from baseline to EOTP [ Time Frame: from baseline to EOTP ]
  • Change in BSI Anxiety scale score from baseline to EOTP [ Time Frame: from baseline to EOTP ]
  • Change in BSI Depression scale score from baseline to EOTP [ Time Frame: from baseline to EOTP ]
  • Change in number of caregiver hours from baseline to EOTP [ Time Frame: from baseline to EOTP ]
  • Incidence of a confirmed antibody formation to darbepoetin alfa [ Time Frame: throughout study ]

Enrollment: 391
Study Start Date: February 2004
Study Completion Date: April 2005
Primary Completion Date: March 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Darbepoetin alfa - Group A Drug: Darbepoetin alfa
Q3W 300 mcg darbepoetin alfa
Placebo Comparator: Placebo- Group B Drug: Placebo
Q3W dosing of placebo


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects with non-myeloid malignancy
  • At least 12 additional weeks of cyclic cytotoxic chemotherapy anticipated regardless of schedule
  • Hemoglobin concentration less than 11.0 g/dL within 24 hours before randomization
  • Adequate serum folate and vitamin B12
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
  • Of legal age at the time written informed consent is obtained

Exclusion Criteria:

  • Known history of seizure disorder
  • Known primary hematologic disorder causing anemia other than non-myeloid malignancies
  • Unstable/uncontrolled cardiac condition
  • Clinically significant inflammatory disease
  • Other diagnoses not related to the cancer which can cause anemia
  • Inadequate renal and liver function
  • Iron deficiency
  • Known positive test for HIV infection
  • Previously suspected of or confirmed to have neutralizing antibodies to rHuEPO
  • Received more than 2 red blood cell (RBC) transfusions within 4 weeks of randomization; or any RBC transfusion within 14 days before randomization; or any planned RBC transfusion between randomization and study day 1
  • Received any erythropoietic therapy within 4 weeks of study day 1 or any planned erythropoietic therapy between randomization and study day 1
  • Other investigational procedures
  • Currently enrolled in or has not yet completed at least 30 days since ending other investigational device or drug trial(s), or subject receiving other investigational agent(s)
  • Pregnant or breast feeding
  • Not using adequate contraceptive precautions
  • Previously randomized into this study
  • Known hypersensitivity to any products to be administered
  • Concerns for subject's compliance
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00110955

Sponsors and Collaborators
Study Director: MD Amgen
  More Information

Additional Information:
Responsible Party: Global Development Leader, Amgen Inc. Identifier: NCT00110955     History of Changes
Other Study ID Numbers: 20030232
Study First Received: May 16, 2005
Last Updated: January 14, 2010

Keywords provided by Amgen:
Non-myeloid malignancy
Chemotherapy-induced anemia

Additional relevant MeSH terms:
Hematologic Diseases
Darbepoetin alfa
Hematinics processed this record on May 25, 2017